Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

July 9, 2021

Study Completion Date

March 27, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

AdCLD-CoV19

Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.

Trial Locations (5)

Korea University Ansan Hospital, Ansan

The Catholic University of Korea, ST. Vincent's Hospital, Suwon

Hallym University Kangnam Sacred Heart Hospital, Seoul

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

Korea University Guro Hospital, Seoul

All Listed Sponsors

lead

Cellid Co., Ltd.

INDUSTRY

NCT04666012 - Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers | Biotech Hunter | Biotech Hunter